Pluristem Therapeutics (PSTI)

Pluristem (PSTI) Stock Price & Analysis


PSTI Stock Chart & Stats

Day’s Range$0.95 - $1.05
52-Week Range― - ―
Previous Close$1.03
Average Volume (3M)N/A
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding32,347,584
10 Day Avg. Volume109,652
30 Day Avg. Volume80,184
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)142.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside600.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Pluristem Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Pluristem Therapeutics’s market cap?
Currently, no data Available
When is Pluristem Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pluristem Therapeutics’s earnings last quarter?
Currently, no data Available
Is Pluristem Therapeutics overvalued?
According to Wall Street analysts Pluristem Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Pluristem Therapeutics pay dividends?
    Pluristem Therapeutics does not currently pay dividends.
    What is Pluristem Therapeutics’s EPS estimate?
    Pluristem Therapeutics’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Pluristem Therapeutics have?
    Currently, no data Available
    What happened to Pluristem Therapeutics’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Pluristem Therapeutics?
    Among the largest hedge funds holding Pluristem Therapeutics’s share is ARK Investment Management LLC. It holds Pluristem Therapeutics’s shares valued at N/A.


      Pluristem Stock Smart Score

      This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
      Learn more about TipRanks Smart Score

      Company Description

      Pluristem Therapeutics

      Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.


      Forecast EPS vs Actual EPS

      Currently, no data available
      Please return soon. This page is being updated.

      Similar Stocks
      Price & Change
      United Therapeutics
      Capricor Therapeutics

      Popular Stocks

      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis